Escientia establishes subsidiary in the Basel Area
The U.S. company Escientia Life Sciences Group has established a subsidiary in the canton of Basel-Landschaft. Escientia Switzerland will offer services to innovators and biotech startups at its Schweizerhalle facility.
Escientia's logo being assembled in Schweizerhalle (img: Escientia)
The new Escientia Switzerland subsidiary of the Escientia Life Sciences Group is based in Schweizerhalle, the industrial complex in the municipalities of Muttenz and Pratteln. The U.S. company offers services in the areas of drug discovery, development, production and commercialization. In the Getec Park in Schweizerhalle, Escientia has newly acquired a plant previously operated by Novartis. The investment and innovation promotion agency Basel Area Business & Innovation as well as the Standortförderung Baselland supported Escientia in establishing the subsidiary.
Escientia Switzerland will invest a two-digit million Swiss franc amount to modernize the plant and install manufacturing facilities for drug substance production. The 17,000 square meter site will then be providing services to large innovators and biotech startups in the Basel Area.
Alongside the various life sciences companies in the region that might be potential customers of Escientia, the U.S. company will also benefit from the highly qualified employees that the Basel Area has to offer. For this year alone, the creation of approximately 60 jobs is planned.
Share this article
You may also be interested in
The Basel-based firm MTIP AG specializes in investments in HealthTech companies. A total of 130 million euros has already been...Read More
The U.S. company Escientia Life Sciences Group has established a subsidiary in the canton of Basel-Landschaft. Escientia Switzerland will offer...Read More